Dec 11 (Reuters) - AnaptysBio ( ANAB ) said on Wednesday

it would end the development of its eczema drug after it failed

to meet the main and secondary goals of a mid-stage trial.

The company's shares were halted during premarket trade.

The drug, ANB032, did not meet the primary goal of the

proportion of patients who achieved at least a 75% improvement

from baseline on an eczema severity index.

The company will focus on the rest of its autoimmune

portfolio, which includes drugs for rheumatoid arthritis and a

type of inflammatory bowel disease, CEO Daniel Faga said in a

statement.